Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus.

Critical leg ischemia (CLI) complicated by diabetes mellitus (DM), which is a very common and dangerous disease, represents the ultimate stage of peripheral arterial disease. Patients are treated with antiplatelet drugs, statins and limb revascularization, but a significant number of patients are not candidate for revascularization. Literature shows that in such cases, gene therapy could be a perfect therapeutic option.

Treatment of Critical Limb Ischemia by pIRES/VEGF165/HGF Administration.

Background: Prognosis of peripheral artery disease (PAD), especially critical limb ischemia (CLI), is very poor despite the development of endovascular therapy and bypass surgery. Many patients result in having leg amputation. We decided to investigate the safety and efficacy of plasmid of internal ribosome entry site/vascular endothelial growth factor (VEGF) 165/hepatocyte growth factor (HGF) gene therapy (GT) in patients suffered from CLI.

An analysis of the impact of clinico-pathological features on long-term results following esophagectomy due to squamous cell carcinoma of the thoracic esophagus.

Background: Squamous cell carcinoma of the esophagus is one of the neoplasms characterized by an exceptionally latent course, dynamic development and poor prognosis. The stage of the disease at the time of treatment is started the greatest impact on the long term results.

Objectives: The aim of this study was to evaluate selected clinical-pathological features as prognostic factors for long term survival among patients who have undergone esophagectomies due to squamous cell carcinoma.